Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 26, Art. 7 (pp. 142-169)    |    2025       

»

Dopamine agonists cause fibrosis? Comparative morphological study of different adenomas of pituitary

Guseva K.A., Lazareva A.A., Matsueva I.A., Paltsev A.A., Grineva E.N., Mitrofanova L.B.

Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation. Postal address: 197341, Russia, St. Petersburg, st. Akkuratova, 2

Brief summary

Prolactinomas account for 40-60% of the total number of pituitary adenomas. The first line of their treatment, unlike other adenomas, are dopamine agonists, however, according to some studies, they can cause fibrosis. The aim of the work was to analyze 42 clinical cases with an assessment of the area of fibrosis in various adenomas in patients who received and did not receive treatment with cabergoline. Materials and methods. On histological sections of 22 prolactinomas, 10 corticotropin, 10 zero-cell adenomas stained with Masson trichrome, the relative area of fibrosis was calculated, then an immunohistochemical study (IHC) was carried out with 6 hormones of the adenohypophysis. The search for statistical differences was carried out using the nonparametric Kruskal-Wallis criterion and Spearman's rank correlation analysis. Results. Among patients with a clinical diagnosis of prolactinoma, according to the results of IHCI, 19 prolactinomas, 1 plurihormonal adenoma, 2 mammosomatropinomas were detected, among which 11 of 22 cases with fibrosis were detected with a mean value of 11.08 ± 18.94%. Among patients with corticotropinomas, 9 of 10 cases with fibrosis were detected with a mean value of 7.12 ± 6.49%. Among patients with zero-cell adenomas, 5 of 10 cases with fibrosis were detected with a mean value of 4.46 ± 6.73%. There was no statistically significant difference in the relative area of fibrosis between the groups of patients who received and did not receive cabergoline. Conclusion. No statistically significant difference in the relative area of fibrosis in different groups of adenomas was found. Therefore, cabergoline does not cause fibrosis.


Key words

pituitary adenoma; prolactinoma; cabergoline; dopamine agonists; fibrosis.

Reference list

1. La Rosa S., Uccella S. Pituitary Tumors: Pathology and Genetics. Reference Module in Biomedical Sciences. 2018. - P. 241-256. https://doi.org/10.1016/b978-0-12-801238-3.65086-9


2. Liu X., Tang C., Wen G., et al. The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas. Front Endocrinology (Lausanne). 2019; 9:768. https://doi.org/10.3389/fendo.2018.00768


3. Mitrofanova L.B., Konovalov P.V., Krilova U.S., i dr. Plurigormonalnie kletki adenogipofiza. Novie vozmojnosti optimizacii molekylyarnoi diagnostiki neiroendokrinnih opyholei. Molekylyarnaya medicina. 2017; 15 (6). - C. 38-45.


4. Kelly M.A., Rubinstein M., Asa S.L., et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 1997; 19. - P. 103-113. https://doi.org/10.1016/s0896-6273(00)80351-7


5. Yatavelli R.K.R., Bhusal K. Prolactinoma. Louisiana State University Health Sciences Center. 2023; 31.


5. Molitch M.E. Diagnosis and Treatment of Pituitary Adenomas. Journal of the American Medical Association. 2017; 317(5). https://doi.org/10.1001/jama.2016.19699


6. Pecorari I.L., Qama E., Akbar N., et al. The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series. Journal of Neurological Surgery Reports. 2024; 85(2). - P. 66-73. https://doi.org/10.1055/s-0044-1786740


7. Chen Z., Shou X., Ji L., Cheng H., et al. Presurgical Medical Treatment in Prolactinomas: Surgical Implications and Pathological Characteristics From 290 Cases. The Journal of Clinical Endocrinology and Metabolism. 2024; 109(6). - P. 1433-1442. https://doi.org/10.1210/clinem/dgad758


8. Liu J.C., Baker R.E., Sun C., et al. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. Journal of Biological Chemistry. 2002; 277. https://doi.org/10.1074/jbc.m202920200


9. Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2018;109(1). - P. 42-50. https://doi.org/10.1159/000495775


10. Radl D.B., Ferraris J., Boti V., et al. Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor. PLOS ONE. 2011; 6. https://doi.org/10.1371/journal.pone.0018097


11. Lin S.J., Leng Z.G., Guo Y.H., et al. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline. Oncotarget. 2015; 6. https://doi.org/10.18632/oncotarget.5744


12. Liu X., Tang C., Wen G., et al. The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas. Front Endocrinology (Lausanne). 2019; 22; 9. https://doi.org/10.3389/fendo.2018.00768.


13. Sarkar D.K., Chaturvedi K., Oomizu S., et al. Dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology. 2005; 146(10). https://doi.org/10.1210/en.2005-0430


14. Colao A., Lombardi G., Annunziato L. Cabergoline. Expert Opinion on Pharmacotherapy. 2000;1. https://doi.org/10.1517/14656566.1.3.555


15. Tang C., Sun R., Wen G., et al. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively. Cell Death & Disease. 2019;10(5). https://doi.org/10.1038/s41419-019-1526-0


16. dos Santos N. V., El Dib R, Boguszewski C.L., Nogueira C.R.. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011; 14(3). https://doi.org/10.1007/s11102-010-0290-z


17. Gomes-Porras M., Cárdenas-Salas J., Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. International Journal of Molecular Sciences. 2020; 21(5). https://doi.org/10.3390/ijms21051682


18. Grigorev A.U., Azizyan V.N., Ivashenko O.V., Starkov G.U. Diagnostika i novie vozmojnosti lecheniya adenom gipofiza. Problemi Endokrinologii. 2023; 69(2). - S. 4-10.


19. Menucci M, Quiñones-Hinojosa A, Burger P, Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary. 2011; 14(1). - P. 68-74. https://doi.org/ 10.1007/s11102-010-0261-4


20. Acitores Cancela A, Rodríguez Berrocal V, Pian-Arias H, et al. Letter to the Editor Regarding "The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series". Journal of Neurological Surgery Reports. 2024; 85(4). https://doi.org/10.1055/s-0044-1791504


21. Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2019; 109(1). - P. 42-50. https://doi.org/10.1159/000495775


22. Shytova A.S, Dzeranova L.K., Vorotnikova S.U., i dr. Sovremennie predstavleniya o geneticheskih i immynogistohimicheskih osobennostyah prolaktinsekretiryushih adenom gipofiza. Problemi endokrinologii. 2023; 69(3). - S.44-50


23. Brue T., Delemer B. Diagnosis and management of hyperprolactinemia: expert consensus. French Society of Endocrinology, Annales d'Endocrinologie. 2007; 68(1) - P. 58-64. https://doi.org/10.1016/j.ando.2006.11.001

Журнал основан 16 ноября 2000г.
Выдано Министерством РФ по делам печати, телерадиовещания и средств массовых коммуникаций

(c) Перепечатка материалов сайта Medline.Ru возможна только с письменного разрешения редакции